Ani Pharmaceuticals Inc. (ANIP)
ANI Pharmaceuticals' 2026 Catalysts Include Gout Push and New Generics
ANIP eyes 2026 growth via Cortrophin's gout push and steady generics launches, as Rare Disease expansion reshapes priorities and investor focus.
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
How Much Upside is Left in ANI (ANIP)? Wall Street Analysts Think 41.71%
The consensus price target hints at a 41.7% upside potential for ANI (ANIP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ANI (ANIP) Upgraded to Strong Buy: Here's Why
ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
ANI Pharmaceuticals Looks Undervalued As Cortrophin Drives Rare Disease Growth
ANI Pharmaceuticals continues shifting toward rare diseases, with management projecting that this segment will represent 60% of its 2026 revenues. However, their generics remain a reliable cash engine. These products grew 28% in 2025 and reached $384 million in revenues. This way, ANIP has been able to fund its expansion into rare diseases, with Cortrophin as its flagship asset in this category.
3 Best Earnings Acceleration Stocks to Buy Now for April 2026
INTU, ANIP and GLPI stand out this April as earnings acceleration signals potential stock gains before broader market recognition kicks in.
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ANI Pharmaceuticals: Worthy Of A Position
ANI Pharmaceuticals recently offered up solid FY26 guidance with 15% non-GAAP EPS growth and strong momentum from Cortrophin Gel. ANIP's increasing reliance on Cortrophin Gel, projected to reach 52% of FY26 revenue, is offset by patent protection and a complex formulation. The company's balance sheet remains solid, supporting ongoing investments in rare disease expansion and 10–15 annual generic launches.
Why ANI Pharmaceuticals (ANIP) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Can ANI (ANIP) Climb 43.86% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for ANI (ANIP) points to a 43.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ANI Pharmaceuticals 2026 Watchlist: Gout Sales Force and Rare Disease
ANIP eyes 2026 pivot as Rare Disease targets 60% of sales, with Cortrophin growth, gout sales force expansion, and retina rebound shaping momentum.
